🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521062-10-00
Authorised Phase I

A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation

2025-521062-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
Arvinas Operations Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
12/03/2026
Enrollment target
51
Sites
Spain, Italy

Condition studied

KRAS G12D Mutated Advanced Solid Tumors

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521062-10-00 on CTIS ↗ ← All trials in the EU